AOCNP (ADVANCED ONCOLOGY CERTIFIED
NURSE PRACTITIONER) EXAM (BY ONCC) |
ULTIMATE QUESTION BANK WITH VERIFIED
CORRECT ANSWERS | GUARANTEED SUCCESS
1. A patient with breast cancer is receiving
doxorubicin (Adriamycin). The oncology nurse
practitioner (NP) is monitoring for cardiotoxicity. The
recommended cumulative lifetime dose limit for
doxorubicin is:
A) 300 mg/m²
B) 450 mg/m²
C) 550 mg/m²
D) 700 mg/m²
Correct answer: C
Rationale: The cumulative lifetime dose limit for
doxorubicin is 550 mg/m² (450 mg/m² if prior chest
radiation).
2. A patient receiving cisplatin develops a sudden
onset of tinnitus and high-frequency hearing loss.
Under ONS guidelines, the NP should:
,A) Continue cisplatin at the same dose
B) Reduce the cisplatin dose by 25%
C) Discontinue cisplatin and consider carboplatin
D) Administer amifostine before the next dose
Correct answer: C
Rationale: Cisplatin-induced ototoxicity is often
irreversible; discontinuation is recommended.
3. A patient with non-Hodgkin lymphoma is receiving
rituximab (Rituxan). The NP observes the patient
experiencing chills, fever, and hypotension during
the first infusion. This reaction is most consistent
with:
A) Anaphylaxis
B) Tumor lysis syndrome
C) Infusion-related reaction (cytokine release
syndrome)
D) Capillary leak syndrome
Correct answer: C
,Rationale: Rituximab commonly causes infusion-
related reactions (cytokine release) during the first
infusion.
4. A patient with metastatic colon cancer is started
on FOLFOX (5-FU, leucovorin, oxaliplatin). The NP
instructs the patient to avoid cold drinks and cold air
due to risk of:
A) Mucositis
B) Hand-foot syndrome
C) Oxaliplatin-induced cold dysesthesia
(laryngopharyngeal dysesthesia)
D) Peripheral neuropathy (warm sensation)
Correct answer: C
Rationale: Oxaliplatin causes acute cold-induced
dysesthesia (throat discomfort, muscle contractions).
5. A patient with chronic myeloid leukemia (CML) on
imatinib (Gleevec) develops periorbital edema and a
maculopapular rash. Under NCCN guidelines, the NP
should:
A) Discontinue imatinib permanently
, B) Prescribe a diuretic and topical steroids; continue
imatinib
C) Switch to dasatinib immediately
D) Administer epinephrine
Correct answer: B
Rationale: Mild to moderate edema and rash are
manageable with supportive care; dose reduction
may be considered.
6. A patient receiving high-dose methotrexate for
osteosarcoma has a methotrexate level of 15
micromol/L at 24 hours. The NP orders leucovorin
rescue. The appropriate dose of leucovorin is based
on:
A) The patient’s weight
B) The serum methotrexate level
C) The patient’s creatinine clearance
D) The patient’s age
Correct answer: B
NURSE PRACTITIONER) EXAM (BY ONCC) |
ULTIMATE QUESTION BANK WITH VERIFIED
CORRECT ANSWERS | GUARANTEED SUCCESS
1. A patient with breast cancer is receiving
doxorubicin (Adriamycin). The oncology nurse
practitioner (NP) is monitoring for cardiotoxicity. The
recommended cumulative lifetime dose limit for
doxorubicin is:
A) 300 mg/m²
B) 450 mg/m²
C) 550 mg/m²
D) 700 mg/m²
Correct answer: C
Rationale: The cumulative lifetime dose limit for
doxorubicin is 550 mg/m² (450 mg/m² if prior chest
radiation).
2. A patient receiving cisplatin develops a sudden
onset of tinnitus and high-frequency hearing loss.
Under ONS guidelines, the NP should:
,A) Continue cisplatin at the same dose
B) Reduce the cisplatin dose by 25%
C) Discontinue cisplatin and consider carboplatin
D) Administer amifostine before the next dose
Correct answer: C
Rationale: Cisplatin-induced ototoxicity is often
irreversible; discontinuation is recommended.
3. A patient with non-Hodgkin lymphoma is receiving
rituximab (Rituxan). The NP observes the patient
experiencing chills, fever, and hypotension during
the first infusion. This reaction is most consistent
with:
A) Anaphylaxis
B) Tumor lysis syndrome
C) Infusion-related reaction (cytokine release
syndrome)
D) Capillary leak syndrome
Correct answer: C
,Rationale: Rituximab commonly causes infusion-
related reactions (cytokine release) during the first
infusion.
4. A patient with metastatic colon cancer is started
on FOLFOX (5-FU, leucovorin, oxaliplatin). The NP
instructs the patient to avoid cold drinks and cold air
due to risk of:
A) Mucositis
B) Hand-foot syndrome
C) Oxaliplatin-induced cold dysesthesia
(laryngopharyngeal dysesthesia)
D) Peripheral neuropathy (warm sensation)
Correct answer: C
Rationale: Oxaliplatin causes acute cold-induced
dysesthesia (throat discomfort, muscle contractions).
5. A patient with chronic myeloid leukemia (CML) on
imatinib (Gleevec) develops periorbital edema and a
maculopapular rash. Under NCCN guidelines, the NP
should:
A) Discontinue imatinib permanently
, B) Prescribe a diuretic and topical steroids; continue
imatinib
C) Switch to dasatinib immediately
D) Administer epinephrine
Correct answer: B
Rationale: Mild to moderate edema and rash are
manageable with supportive care; dose reduction
may be considered.
6. A patient receiving high-dose methotrexate for
osteosarcoma has a methotrexate level of 15
micromol/L at 24 hours. The NP orders leucovorin
rescue. The appropriate dose of leucovorin is based
on:
A) The patient’s weight
B) The serum methotrexate level
C) The patient’s creatinine clearance
D) The patient’s age
Correct answer: B
